Research
Energy balance
The integration of digital health and artificial intelligence is expected to advance antiobesity drug development.
Practitioners should consider how digital health tools and AI may enhance treatment strategies for obesity.
ModerateSupportsmedium confidence
The review also explored emerging innovations such as ultralong-acting formulations, combination therapies, and the integration of digital health and artificial intelligence in advancing antiobesity drug development.
Why this rating
The claim is based on a narrative review discussing potential innovations.
Source
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Riad Mohammed Abdelrahman et al. · Journal of Obesity · 2025
DOI 10.1155/jobe/9919810
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.Strong
- By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications including chronic kidney disease and heart failure.Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →